Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2023

New therapeutic classes: ADCs, bispecifics and novel IO agents

Cancer vaccines

Date

31 Mar 2023

Session

New therapeutic classes: ADCs, bispecifics and novel IO agents

Topics

Tumour Immunology;  Translational Research;  Immunotherapy

Tumour Site

Presenters

Pedro Romero

Authors

P. Romero

Author affiliations

  • Lausanne/CH

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Antibody drug conjugates

Presenter: Daniel Shao Weng Tan

Session: New therapeutic classes: ADCs, bispecifics and novel IO agents

Resources:

Slides

Webcast

Bispecific antibodies

Presenter: Fiona Blackhall

Session: New therapeutic classes: ADCs, bispecifics and novel IO agents

Resources:

Slides

Webcast

Novel checkpoints

Presenter: Jarushka Naidoo

Session: New therapeutic classes: ADCs, bispecifics and novel IO agents

Resources:

Slides

Webcast

Q&A

Presenter: Fiona Blackhall

Session: New therapeutic classes: ADCs, bispecifics and novel IO agents

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.